Abbott unveils Libre Assist, a GenAI powered feature that helps people with diabetes predict glucose impact from meals before eating.
Understanding how food affects blood glucose remains a daily challenge for people with diabetes. Visual cues rarely reveal nutritional impact. At CES 2026 in Las Vegas, Abbott introduced Libre Assist, a GenAI feature inside the Libre app. The tool targets decision-making before eating, not after glucose spikes occur. This shift addresses a long-standing gap in diabetes self-management.
Libre Assist uses GenAI to analyze meal photos or written descriptions. The system identifies ingredients and estimates glucose impact in advance. Predictions are personalized using user-provided food preferences and historical data. Results appear as simple color ratings, ranging from green to orange. This reduces cognitive burden during meals, especially when dining out or traveling.
The GenAI model overcomes fragmented nutrition data and inconsistent labeling. It translates unstructured visual and text inputs into actionable metabolic predictions. Libre Assist also suggests food swaps to reduce glucose impact. For example, it may recommend plain yogurt instead of flavored options. These recommendations adapt to dietary preferences, supporting adherence without rigid meal planning.
Integration with FreeStyle Libre continuous glucose monitors closes the feedback loop. After eating, the app compares predicted impact with real glucose responses. This helps users understand variability caused by stress, activity, medication, or alcohol. Over time, GenAI learns from outcomes, improving accuracy and personalization. Abbott positions Libre Assist as a global digital health tool, scalable across regions and diets.
